goal
establish
flexibl
product
platform
highyield
cell
culturederiv
influenza
vaccin
manufactur
celllin
screen
identifi
one
hand
adher
grow
cell
mdck
madin
darbi
canin
kidney
vero
african
green
monkey
kidney
cell
hand
suspens
cell
mdck
cell
kessler
et
al
pau
et
al
brand
et
al
kistner
et
al
nakamura
homma
sandig
jordan
vorlop
le
ru
et
al
cell
line
show
specif
use
vaccin
product
advantag
also
disadvantag
compar
cell
line
base
thorough
understand
pro
con
individu
host
cell
process
perform
properti
cell
line
specif
aspect
cell
interact
process
option
better
evalu
overal
thorough
comparison
cell
line
might
help
develop
process
optim
strategi
well
assess
qualiti
differ
concern
viru
strain
antigen
produc
last
decad
use
adher
cell
influenza
viru
manufactur
attract
much
attent
kistner
et
al
barrett
et
al
tree
et
al
particular
growth
influenza
viru
replic
adher
grow
mdck
vero
cell
investig
rimmelzwaan
et
al
merten
et
al
b
nicolson
et
al
howev
direct
comparison
experiment
data
two
cell
line
ie
identif
cell
line
result
optimum
process
perform
straight
forward
one
side
cell
viru
propag
investig
differ
cultiv
system
static
system
roller
bottl
spinner
stir
tank
side
differ
media
serumcontain
sc
well
serumfre
sf
also
differ
microcarri
cytodex
use
largescal
cultur
merten
et
al
quesney
et
al
kistner
et
al
mendonca
pereira
addit
variat
result
use
mdck
well
vero
cell
line
differ
sourc
use
differ
influenza
viru
strain
genzel
reichl
even
similar
cultiv
condit
chosen
differ
product
well
product
qualiti
expect
exampl
vero
cell
known
defici
respons
due
absenc
gene
mosca
desmyt
et
al
typic
cell
line
two
differ
host
also
show
variat
glycosyl
machineri
metabol
enzym
activ
proteom
level
ritter
et
al
schwarzer
et
al
kistner
et
al
describ
use
adher
vero
cell
influenza
vaccin
product
compar
product
differ
viru
strain
egg
vero
cell
kistner
et
al
scaleup
l
stir
tank
reactor
str
use
cell
concentr
cellsml
obtain
use
cytodex
microcarri
viru
infect
done
later
kistner
et
al
discuss
success
product
inactiv
whole
viru
vaccin
vero
cell
kistner
et
al
barrett
et
al
shown
cell
culturederiv
influenza
product
addit
trypsin
time
infect
result
fast
cleavag
hemagglutinin
ha
need
success
infect
decreas
viru
titer
pfuml
slower
viru
product
describ
trypsin
ad
viru
mainten
medium
roller
bottl
tree
et
al
typic
trypsin
ad
sever
time
influenza
product
vero
cell
cell
releas
trypsin
inhibitor
kaverin
webster
romanova
et
al
mdck
cell
releas
trypsin
inhibitor
also
describ
recent
nishiyama
et
al
howev
influenza
viru
replic
found
sensit
trypsin
concentr
vero
cell
trypsin
usual
ad
time
infect
tree
et
al
genzel
et
al
b
schwartz
et
al
final
viru
adapt
produc
cell
line
often
describ
adapt
egg
cell
lin
et
al
genzel
reichl
govorkova
et
al
passag
need
obtain
accept
ha
viru
titer
howev
typic
three
four
passag
need
nevertheless
virus
abl
prolifer
host
cell
line
tobita
et
al
stabil
produc
viru
well
influenc
multipl
infect
moi
trypsin
addit
adapt
result
vari
ha
titer
infect
time
rimmelzwaan
et
al
wressnigg
et
al
audsley
tannock
youil
et
al
harvest
time
point
might
therefor
crucial
viru
titer
also
screen
high
titer
done
without
time
profil
infect
follow
present
thorough
analysi
impact
infect
paramet
trypsin
concentr
cultiv
medium
human
influenza
viru
product
adher
vero
mdck
cell
viru
seed
adapt
cell
line
differ
viru
propag
data
stabil
viru
analyz
variou
human
influenza
strain
smallscal
cultiv
system
roller
bottl
tflask
two
media
addit
ha
nglycan
analysi
perform
ass
cellspecif
differ
ha
nglycosyl
pattern
final
cultiv
condit
result
similar
viru
yield
cell
line
smallscal
cultiv
evalu
stir
tank
wave
bioreactor
use
two
differ
media
adher
mdck
cell
ecacc
adher
vero
cell
seed
ecacc
either
cultiv
serumcontain
condit
gmem
gibco
describ
genzel
et
refer
sc
follow
serumfre
condit
episerf
gibco
supplement
glucos
final
concentr
sigma
glutamin
final
concentr
sigma
pyruv
final
concentr
sigma
genzel
et
al
medium
refer
sf
medium
follow
cell
cultiv
sf
medium
least
three
passag
experi
done
viru
product
requir
serumfre
medium
maximum
trypsin
activ
cell
cultiv
sc
medium
wash
phospatebuff
salin
pb
prior
infect
remov
serum
medium
chang
medium
medium
base
sc
medium
without
serum
addit
cell
cultiv
sf
medium
directli
infect
condit
low
level
porcin
trypsin
ad
facilit
infect
cell
therefor
sterilefilt
stock
solut
trypsin
gibco
prepar
pb
unitsml
accord
activ
given
supplier
viru
product
follow
titrat
viral
ha
tissu
cultur
infecti
dose
govorkova
et
al
genzel
et
al
b
viru
seed
supplier
eggadapt
passag
least
three
time
mdck
cell
produc
master
work
viru
seed
medium
product
refer
mdck
cellderiv
viru
seed
store
aliquot
viru
adapt
product
vero
cell
done
passag
mdck
cellderiv
viru
seed
four
time
vero
cell
tflask
govorkova
et
al
mdck
cellderiv
viru
seed
abbrevi
mdck
adapt
use
human
influenza
suppli
nation
institut
biolog
standard
control
nibsc
code
robert
koch
institut
rki
code
amp
human
influenza
hgr
nibsc
nibsc
code
prepar
nymc
reassort
np
gene
human
influenza
nibsc
nibsc
code
vero
cellderiv
viru
seed
abbrevi
va
vero
adapt
use
human
influenza
adapt
nibscmdck
cellderiv
viru
seed
rkimdck
cellderiv
viru
seed
human
influenza
adapt
mdck
cellderiv
viru
seed
rollerbottl
cultur
rb
greiner
inocul
approxim
cell
grown
four
day
ml
sc
sf
medium
cap
tightli
close
fulli
confluent
cell
cell
infect
moi
base
viru
seed
grown
sc
medium
bottl
wash
three
time
pb
without
addit
medium
sf
medium
infect
done
without
wash
step
medium
exchang
preliminari
experi
show
medium
suffici
support
cell
growth
viru
replic
seen
differ
sf
medium
genzel
et
al
b
tflask
greiner
experi
carri
accordingli
condit
use
l
stir
tank
bioreactor
describ
genzel
et
al
microcarri
cytodex
ge
healthcar
ad
medium
final
concentr
gl
start
cell
concentr
cellsml
four
day
cultiv
cell
grown
confluent
human
influenza
hgr
viru
seed
trypsin
solut
ad
moi
adjust
base
viru
seed
detail
see
tabl
preliminari
experi
shown
lower
moi
result
slightli
higher
ha
titer
data
shown
end
viru
product
step
indic
increas
empti
microcarri
cultiv
stop
rollerbottl
precultur
sf
medium
cultiv
describ
genzel
et
al
b
fulli
confluent
cell
cell
wash
three
time
pb
ml
without
detach
exposur
trypsinedta
solut
ml
min
gl
trypsin
gibco
gl
edta
merck
incub
mdck
cell
min
vero
cell
min
reaction
stop
ml
sf
medium
cell
suspens
use
inocul
l
wave
bioreactor
cellbag
work
volum
condit
use
l
wave
bioreactor
describ
genzel
et
al
b
cultiv
l
wave
bioreactor
wave
biotech
ag
sf
medium
l
microcarri
prepar
describ
genzel
et
al
b
gl
cell
start
cell
concentr
cellsml
ad
feed
bottl
transfer
cellbag
wave
biotech
ag
ldpe
materi
detail
see
tabl
reactor
set
temperatur
platform
angl
rock
rate
rocksmin
aerat
mix
air
nlmin
genzel
et
al
b
concentr
set
manual
shown
fig
infect
viru
human
influenza
rki
trypsin
ad
ml
fresh
sf
medium
afterward
medium
transfer
cellbag
cell
concentr
higher
cellsml
reach
moi
remov
spent
medium
infect
neither
ph
control
sampl
prepar
storag
well
determin
cell
concentr
cell
viabil
metabolit
viru
titer
carri
describ
previous
genzel
reichl
genzel
et
al
mahi
kangro
error
differ
valid
assay
describ
earlier
smallscal
experi
given
ha
titer
express
log
base
dilut
error
ha
log
ha
assay
visual
readout
chickenerythrocyt
solut
set
cellsml
bioreactor
cultiv
sensit
ha
assay
use
well
well
dilut
readout
use
plate
reader
nm
evalu
boltzmann
sigmoid
fit
readout
ha
rel
standard
deviat
method
kalbfuss
et
al
determin
dilut
error
log
genzel
reichl
sampl
wave
bioreactor
cellbag
ml
taken
syring
luerlockseptum
interv
cell
growth
viru
product
determin
cell
concentr
microcarri
carri
describ
genzel
reichl
nglycan
analysi
done
accord
schwarzer
et
al
viru
harvest
purifi
concentr
consecut
stepwis
gforc
gradient
centrifug
redissolv
pellet
viru
protein
separ
sdspage
ingeldeglycosyl
perform
accord
kuster
et
al
nglycan
extract
gel
piec
complet
dri
integr
speedvac
system
savant
subsequ
glycan
fluoresc
label
acid
apt
sigmaaldrich
reduct
amin
callewaert
et
al
aptsconjug
nglycan
desalt
multiscreen
deep
well
solvinert
filter
plate
millipor
mdrl
pack
size
exclus
chromatographi
sec
materi
separ
conjug
nglycan
surplu
dye
done
modifi
methacryl
polym
base
toyopearl
nglycancontain
fraction
identifi
scan
typhoon
trio
variabl
mode
imag
ge
healthcar
capillari
gel
electrophoresislaserinduc
fluoresc
cgelif
perform
accord
callewaert
et
al
appli
biosystem
abi
prism
genet
analyz
equip
genet
analyz
capillari
array
effect
capillari
length
cm
undilut
polym
appli
biosystem
separ
matrix
obtain
nglycan
fingerprint
normal
intern
standard
use
supplier
softwar
packag
preliminari
experi
viru
product
vero
cell
use
influenza
viru
seed
produc
mdck
cell
result
rel
low
ha
titer
furthermor
took
compar
long
time
reach
maximum
ha
titer
howev
adapt
least
three
passag
vero
cell
influenza
variant
influenza
hgr
signific
improv
obtain
fig
surprisingli
influenza
could
adapt
replic
vero
cell
ha
titer
detect
limit
even
differ
adapt
strategi
appli
eg
chang
temperatur
fast
slow
passag
sf
medium
nglycan
fingerprint
ha
protein
fraction
influenza
nibsc
monitor
adapt
process
expect
nglycan
fingerprint
produc
ha
protein
differ
mdck
vero
cell
first
adapt
step
nglycan
fingerprint
chang
fig
stabil
adapt
step
three
indic
three
step
suffici
success
match
viru
new
host
cell
three
adapt
step
also
enough
obtain
similar
viru
yield
infect
time
profil
vero
cell
compar
mdck
cell
vero
well
mdck
cell
report
releas
proteas
inhibitor
effect
activ
trypsin
infect
kaverin
webster
nishiyama
et
al
develop
product
process
use
serumfre
media
inhibitor
could
neg
effect
viru
product
wash
medium
exchang
step
omit
infect
viru
replic
mdck
cell
seem
margin
effect
proteas
inhibitor
multipl
trypsin
addit
describ
vero
cell
overcom
trypsin
inactiv
govorkova
et
al
evalu
differ
trypsin
concentr
ad
vero
cell
medium
rb
effect
time
cours
viru
replic
maximum
ha
titer
could
seen
test
concentr
fig
howev
sf
medium
without
wash
activ
ucel
need
fast
progress
infect
high
ha
titer
fig
addit
wash
step
infect
routin
requir
medium
cultiv
could
addit
reduc
time
need
reach
maximum
ha
titer
interestingli
multipl
trypsin
addit
result
increas
ha
titer
faster
viru
replic
microcarri
system
howev
str
wave
bioreactor
addit
shear
forc
led
fast
cell
detach
trypsin
concentr
therefor
reduc
concentr
ucel
use
avoid
earli
cell
detach
see
tabl
therefor
trypsin
addit
adapt
individu
media
even
differ
lot
cultiv
system
use
vero
cell
infect
newli
adapt
virus
time
point
harvest
obtain
high
titer
test
differ
virus
viru
seed
stock
prepar
stabil
viru
clearli
influenc
viru
titer
stabil
two
viru
variant
human
influenza
suppli
nibsc
rki
produc
either
mdck
cell
vero
cell
test
therefor
viru
incub
medium
day
rb
earlier
experi
mdck
cell
known
two
variant
result
differ
ha
titer
schulzehorsel
et
al
follow
stabil
equin
influenza
mdck
cell
similar
condit
rb
seen
maximum
ha
titer
rel
constant
wherea
decreas
time
h
infecti
viru
could
detect
genzel
et
al
b
two
differ
variant
human
influenza
surprisingli
nibsc
variant
produc
mdck
cell
similar
decreas
found
h
infecti
viru
could
detect
fig
rki
variant
produc
mdck
vero
cell
nibsc
variant
produc
vero
cell
clearli
higher
stabil
could
seen
titer
approxim
remain
day
maximum
peak
titer
found
h
post
infect
pi
rki
variant
produc
vero
cell
h
pi
h
pi
ha
tabl
describ
earlier
rki
variant
higher
titer
found
compar
nibsc
variant
schulzehorsel
et
al
surprisingli
highest
profil
rki
variant
vero
cell
result
compar
low
ha
profil
maximum
log
ha
final
viru
titer
viru
stabil
analyz
viru
strain
produc
lower
moi
moi
mdck
vero
cell
sf
medium
rel
constant
ha
titer
obtain
maximum
ha
titer
reach
data
shown
sf
medium
also
medium
mdck
cellderiv
virion
seem
less
stabl
vero
cellderiv
virion
tabl
lowest
viru
stabil
k
vi
found
influenza
sf
medium
produc
mdck
cell
howev
maximum
ha
titer
well
high
product
viru
strain
medium
l
str
well
static
cultur
show
good
ha
titer
log
ha
valu
reach
data
shown
indic
poor
viru
stabil
sf
medium
maximum
clearli
higher
vero
cellderiv
compar
mdck
cellderiv
cultiv
interpret
differ
time
point
pi
maxim
ha
titer
obtain
difficult
two
reason
first
lower
moi
use
sf
medium
second
differ
trypsin
concentr
use
vero
mdck
cell
factor
could
influenc
viru
replic
dynam
gener
maximum
ha
titer
typic
h
later
maximum
hgr
produc
mdck
cell
delay
maximum
ha
titer
could
observ
viru
product
influenza
hgr
mdck
cellderiv
seed
vero
cellderiv
seed
respect
carri
cultiv
cell
line
confluenc
l
stir
tank
bioreactor
sc
medium
gl
microcarri
cytodex
mc
vc
see
tabl
cell
line
reach
cellsml
day
cultiv
cellsml
fig
b
glutamin
uptak
ammonia
releas
cell
growth
similar
cell
line
detail
mdck
data
see
genzel
et
al
wherea
glucos
uptak
lactat
releas
clearli
lower
vero
cell
mm
compar
mm
lactat
releas
fig
mdck
cell
took
glutam
complet
end
cell
growth
phase
vero
cell
constantli
releas
glutam
medium
concentr
mm
subsequ
viru
product
phase
vero
cell
show
lower
glucos
uptak
lactat
releas
similar
glutamin
uptak
ammonia
releas
fig
c
produc
ha
titer
lower
vero
cell
ha
mdck
cell
fig
also
correspond
titer
lower
vero
cell
infecti
virionsml
result
cellspecif
product
virionscel
virionscel
overal
viru
product
first
h
slower
vero
cell
mdck
cell
howev
viru
stabil
seem
higher
vero
product
process
cell
line
glutam
releas
mm
could
seen
vero
cell
time
point
increas
seem
correl
ha
titer
glutam
releas
mdck
cell
process
start
clearli
later
h
compar
one
hand
cell
line
perform
sf
medium
without
medium
exchang
viru
infect
hand
cultiv
wave
bioreactor
serumfre
adapt
cell
start
concentr
cellsml
grown
confluenc
gl
cytodex
microcarri
cellsml
mdck
cellsml
vero
fig
vero
cell
howev
requir
h
reach
respect
cell
concentr
subsequ
cell
cellbag
directli
infect
correspond
viru
seed
increas
suspens
cell
decreas
concentr
cell
microcarri
clearli
faster
mdck
cell
infect
case
final
concentr
suspens
cell
detach
correspond
concentr
adher
cell
time
infect
ie
cell
lysi
rate
seem
low
compar
requir
addit
togeth
ph
profil
glucos
uptak
lactat
releas
fig
e
show
start
ph
decreas
mdck
cell
parallel
lactat
releas
result
possibl
decreas
addit
vero
cell
howev
clearli
higher
addit
need
begin
cultiv
ph
stabl
compar
cultiv
mdck
cell
lactat
releas
start
h
lactat
releas
similar
effect
ph
mdck
cultiv
cell
line
molar
yield
coeffici
lacgluc
lower
cell
growth
phase
mdck
vero
compar
viru
replic
phase
mdck
vero
vero
cell
show
phase
lower
coeffici
mdck
cell
glutamin
uptak
ammonia
releas
cell
similar
stir
tank
reactor
fig
medium
vero
cell
releas
glutam
wherea
mdck
cell
show
first
slight
glutam
releas
follow
strong
uptak
cell
line
releas
glutam
viru
product
viru
product
clearli
slower
lower
vero
cell
total
viru
yield
ha
mdck
virionscel
vero
virionscel
howev
infecti
viral
particl
produc
similar
data
obtain
cell
line
virionsml
fig
calcul
ratio
infecti
total
virion
vero
cultiv
result
wherea
mdck
cultiv
led
correspond
experiment
data
obtain
roller
bottl
cultiv
see
tabl
delay
increas
ha
titer
clearli
bigger
vero
cell
mdck
cell
cell
line
increas
ha
titer
increas
viru
product
vero
cell
significantli
improv
respect
maximum
ha
titer
well
time
period
reach
maximum
ha
titer
adapt
mdck
cellderiv
viru
seed
vero
cell
nglycan
fingerprint
maximum
ha
titer
viru
passag
indic
three
four
passag
suffici
adapt
process
howev
success
adapt
seem
depend
strongli
viru
strain
influenza
well
nibsc
code
kind
gift
g
koch
univers
freiburg
germani
could
adapt
replic
vero
cell
data
shown
virus
plum
viru
rinderpest
viru
adapt
also
describ
result
typic
improv
vitro
viru
product
passag
viru
isol
walli
et
al
ishii
et
al
govorkova
et
al
describ
increas
infecti
viru
titer
passag
limit
dilut
influenza
vero
cell
govorkova
et
al
rna
sequenc
analysi
protein
show
chang
due
adapt
process
thu
indic
select
virus
antigen
chang
ha
addit
rna
sequenc
analysi
coldadapt
liveattenu
influenza
virus
use
vaccin
children
show
mutat
relat
attenu
chang
day
vaccin
klimov
et
al
similar
improv
viru
yield
report
govorkova
et
al
also
describ
mdck
cell
compar
titer
passag
two
five
differ
viral
sampl
viru
subtyp
tsai
trusheim
exact
caus
chang
ha
nglycan
fingerprint
adapt
process
yet
clear
previou
find
compar
nglycan
fingerprint
differ
virus
grown
variou
cell
line
show
specif
ha
nglycan
fingerprint
cell
line
combin
schwarzer
et
al
agreement
differ
ha
fingerprint
mdck
vero
cellderiv
viru
observ
studi
chang
glycosyl
influenza
b
virus
grown
egg
mdck
cell
describ
detail
chen
et
al
use
western
blot
sequenc
analysi
protein
chen
et
al
influenza
glycosyl
pattern
result
product
vero
mdck
cell
compar
romanova
et
al
treatment
glycosidas
western
blot
romanova
et
al
shown
adapt
vero
cell
could
longer
infect
chicken
egg
agglutin
chicken
erythrocyt
howev
studi
problem
ha
determin
notic
sampl
vc
cultiv
use
hgr
author
conclud
chang
ha
nglycosyl
like
link
chang
amino
acid
sequenc
chang
singl
amino
acid
also
found
adapt
coronavirus
vero
cell
differ
temperatur
shen
et
al
overal
seem
interrel
ha
nglycosyl
pattern
rna
amino
acid
sequenc
yet
clearli
understood
studi
respect
perform
base
find
assum
chang
ha
nglycan
fingerprint
mainli
depend
host
cell
line
contrast
difficulti
adapt
influenza
b
virus
vero
cell
report
wressnigg
et
al
describ
success
product
viru
strain
sfm
adapt
wressnigg
et
al
vero
cell
differ
origin
atcc
differ
viru
strain
use
clear
explan
discrep
result
report
given
also
decreas
incub
temperatur
improv
viru
yield
test
virus
describ
studi
tobita
et
al
nakamura
homma
discuss
vero
cell
seem
gener
produc
influenza
b
virus
poorli
compar
mdck
cell
nakamura
homma
tobita
et
al
howev
viru
adapt
viru
seed
vero
cell
describ
total
variou
chang
result
passag
virus
differ
cell
line
indic
need
consid
specif
aspect
cell
interact
viru
dynam
maximum
titer
glycosyl
process
optim
well
assess
antigen
qualiti
vaccin
candid
compar
mdck
cell
success
viru
product
vero
cell
depend
viru
adapt
also
strategi
trypsin
addit
mdck
cell
particular
vero
cell
releas
proteas
inhibitor
cell
cultur
medium
affect
activ
trypsin
need
viru
infect
kaverin
webster
nishiyama
et
al
wash
medium
exchang
step
infect
could
clearli
reduc
activ
trypsin
inhibitor
potenti
counteract
success
viru
replic
howev
vaccin
product
process
step
mean
addit
medium
cost
increas
contamin
risk
hand
high
trypsin
activ
viru
product
medium
could
result
cell
detach
therefor
seen
studi
optim
trypsin
activ
essenti
particular
batch
batch
variat
trypsin
media
differ
shear
stress
cultiv
system
need
consid
increas
trypsin
activ
result
earlier
increas
ha
titer
sf
medium
low
concentr
prevent
success
viru
replic
sc
medium
howev
trypsin
concentr
test
result
similar
ha
profil
multipl
addit
trypsin
describ
govorkova
et
al
result
improv
ha
titer
method
would
complic
largescal
product
process
singl
addit
trypsin
time
infect
prefer
test
viru
stabil
differ
mdck
vero
cellderiv
viru
seed
stabl
ha
titer
obtain
least
h
pi
howev
viru
strain
clearli
differ
stabil
especi
mdck
cellderiv
nibsc
medium
show
low
stabil
infecti
virion
detect
h
pi
also
seen
equin
influenza
mdck
cell
h
pi
genzel
et
al
b
viru
strain
test
studi
show
better
stabil
sf
medium
lower
moi
hgr
produc
vero
cell
stabl
tabl
h
differ
influenza
b
virus
sfm
moi
wressnigg
et
al
show
data
h
pi
wressnigg
et
al
viru
strain
stabl
titer
time
frame
shown
maximum
titer
virionsml
reach
influenza
produc
mdck
cell
rimmelzwaan
et
al
also
show
decreas
stabl
ha
titer
time
period
h
rimmelzwaan
et
al
contrast
schwartz
et
al
describ
product
decreas
h
pi
schwartz
et
al
thu
seem
adapt
viru
seed
host
cell
line
well
viru
strain
influenc
viru
stabil
character
determin
optimum
harvest
time
especi
seed
viru
prepar
manufactur
liveattenu
vaccin
vero
cell
use
sinc
mani
year
product
viral
vaccin
spread
vero
cell
onto
cytodex
microcarri
gl
observ
detail
et
al
inocul
found
optimum
cellstomicrocarri
ratio
eight
cell
per
microcarri
lead
cellsml
day
cell
growth
spinner
flask
sc
medium
cultiv
l
stir
tank
bioreactor
result
cellsml
day
batch
cellsml
day
perfus
mode
mendonca
pereira
cultiv
vero
cell
cytodex
gl
shown
quesney
et
al
cellsml
start
concentr
cellsml
obtain
day
studi
spinner
flask
show
optim
ph
attach
vero
cell
onto
cytodex
microcarri
ph
use
serumsupport
cell
growth
cell
attach
ng
et
al
furthermor
continu
stir
rpm
attach
phase
favor
compar
intermitt
stir
product
japanes
enceph
viru
vero
cell
use
gl
cytodex
spinner
flask
result
maximum
cell
concentr
cellsml
day
sf
medium
toriniwa
komiya
product
rabi
viru
vero
cell
shown
vpsfm
medium
use
cytodex
microcarri
gl
l
stir
tank
bioreactor
rourou
et
al
maximum
cell
concentr
cellsml
reach
day
final
merten
et
al
compar
mdck
vero
cell
growth
influenza
infect
sf
medium
merten
et
al
b
vero
cell
maximum
concentr
cellsml
obtain
day
cytodex
microcarri
gl
experiment
data
obtain
studi
sc
medium
well
sf
medium
bioreactor
cytodex
microcarri
gl
thu
compar
report
result
vero
cell
particular
maximum
cell
concentr
cellsml
day
gl
microcarri
reach
thu
chosen
process
condit
result
similar
cell
growth
mdck
vero
cell
preliminari
experi
smallscal
tflask
roller
bottl
optim
condit
direct
comparison
mdck
vero
deriv
influenza
vaccin
product
larger
scale
could
identifi
smallscal
vero
cell
produc
similar
even
higher
viru
titer
mdck
cell
also
condit
lower
titer
possibl
especi
medium
viru
strain
strong
influenc
possibl
titer
product
hgr
sf
medium
vero
cell
show
higher
viru
titer
mdck
cell
ha
well
tabl
hand
cultiv
l
stir
tank
bioreactor
sc
medium
vero
cell
produc
lower
viru
titer
mdck
cell
nevertheless
titer
ha
reason
product
two
differ
influenza
virus
l
scale
bioreactor
kistner
et
al
use
vero
atcc
cell
line
viru
adapt
four
passag
kistner
et
al
moi
infect
ha
titer
ha
obtain
earlier
kistner
et
al
show
differ
viru
strain
comparison
veroderiv
eggderiv
viru
product
ha
titer
ha
typic
obtain
vero
cell
cultiv
shown
l
bioreactor
reach
ha
titer
ha
kistner
et
al
studi
viru
replic
phase
bioreactor
str
wave
concentr
cell
microcarri
decreas
faster
mdck
cell
vero
cell
correspondingli
respect
concentr
mdck
suspens
cell
increas
earlier
indic
faster
induct
virusinduc
apoptosi
cell
vero
mdck
cell
cultiv
media
reactor
type
show
similar
glutamin
uptak
ammonia
releas
slightli
lower
glucos
uptak
respect
lactat
releas
vero
cell
clear
differ
notic
glutam
vero
cell
releas
glutam
constantli
wherea
mdck
cell
took
glutam
complet
toward
end
cell
growth
phase
mendonca
et
al
describ
metabol
vero
cell
leibovitz
medium
supplement
fc
mm
glutamin
stir
tank
bioreactor
cultiv
mendonca
pereira
cell
concentr
cellsml
reach
batch
mode
day
cultiv
observ
uptak
lactat
galactos
use
carbon
sourc
glutamin
uptak
ammonia
releas
similar
chang
glutam
concentr
report
effect
ammonia
glutamineglutam
growth
vero
cell
dmem
medium
analyz
detail
huang
et
al
growth
medium
without
glutamin
contain
glutam
ammonia
ammonia
slightli
taken
ammonia
releas
seen
growth
medium
contain
glutam
glutam
asparagin
growth
glutamin
medium
ammonia
releas
found
similar
releas
observ
studi
glutamatecontain
media
huang
et
al
also
describ
uptak
glutam
similar
found
mdck
cell
sc
medium
studi
medium
howev
contain
glutamin
seem
vero
cell
use
glutam
produc
glutamin
via
enzym
glutamin
synthetas
howev
glutamin
ad
medium
glutamin
taken
prefer
glutamin
synthetas
activ
reduc
case
even
releas
glutam
possibl
work
progress
use
specif
enzym
actviti
assay
jank
et
al
character
cultiv
differ
media
ie
media
contain
glutamin
detail
metabol
vpsfmwilliam
e
medium
stir
tank
bioreactor
perform
similar
condit
describ
studi
also
given
quesney
et
al
quesney
et
al
compar
result
glutamin
uptak
clearli
higher
vpsfmwilliam
e
medium
lead
complet
uptak
day
furthermor
also
releas
glutam
observ
explain
author
transform
glutamin
glutam
vero
cell
also
cultiv
vpsfm
medium
mm
gln
rourou
et
al
rabi
viru
propag
rourou
et
al
although
lower
glucos
start
concentr
use
higher
lactat
level
reach
compar
labscal
cultiv
studi
contrast
glucos
higher
glutamin
start
concentr
use
rourou
et
al
lower
ammonia
releas
observ
glutam
data
given
previou
cultiv
data
mdck
cell
differ
serumfre
medium
wave
bioreactor
similar
condit
genzel
et
al
b
medium
stir
tank
bioreactor
genzel
et
al
show
similar
glucos
uptak
lactat
releas
well
glutamin
uptak
ammonia
releas
uptak
glutam
reactor
media
differ
previous
describ
serumfre
medium
glutam
slightli
releas
genzel
et
al
b
glutamin
metabol
glutam
uptak
releas
regul
cell
still
need
clarif
possibl
approach
would
studi
monitor
intracellular
metabolit
concentr
specif
enzym
activ
ritter
et
al
togeth
concentr
extracellular
substrat
growth
inhibitor
one
hand
comprehens
experiment
data
vero
cell
line
use
product
polio
rabi
vaccin
also
influenza
viru
found
hand
mdck
cell
shown
equal
good
host
cell
influenza
vaccin
manufactur
howev
studi
typic
perform
use
differ
media
cultiv
vessel
cultiv
condit
viru
strain
direct
comparison
host
cell
line
difficult
data
present
allow
better
assess
result
obtain
influenza
viru
product
mdck
vero
cell
emphas
influenc
viru
adapt
trypsin
addit
medium
select
time
harvest
similar
viru
titer
obtain
vero
mdck
cell
condit
optim
smallscal
experi
bioreactor
cultiv
howev
mdck
cell
seem
favor
addit
viru
strain
seem
equal
well
adapt
differ
cell
line
furthermor
differ
result
ha
nglycan
fingerprint
might
relev
immunogen
vaccin
therefor
altern
host
cell
seem
essenti
worldwid
vaccin
product
especi
case
pandem
